Biomarkers
Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning
Frontiers in Endocrinology 2022 November 29 [Link] Yingqi Xiao, Wei Huang, Li Zhang, Hongwei Wang Abstract Background: Glycolysis-related genes as prognostic markers in malignant pleural mesothelioma (MPM) is still unclear. We hope to explore the relationship between glycolytic pathway genes and MPM prognosis by constructing prognostic risk models through bioinformatics and machine learning. Methods: The…
Read MoreIdentification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma
La Medicina del Lavoro 2022 December 7 [Link] Luca Ferrari, Simona Iodice, Laura Cantone, Barbara Dallari, Laura Dioni, Lorenzo Bordini, Alessandro Palleschi, Carolina Mensi, Angela Cecilia Pesatori Abstract Background: Malignant pleural mesothelioma (MPM) is a rare highly aggressive tumor strongly associated with asbestos exposure and characterized by poor prognosis. Currently, diagnosis is based on invasive…
Read MoreHistopathological and immunohistochemical features of 14 peritoneal mesotheliomas with clinical outcomes and recent updates
Journal of Cancer Research and Therapeutics 2022 Oct-Dec [Link] Srushti Karmarkar, Bharat Rekhi, Kedar K Deodhar, Santosh Menon Abstract Background: Malignant peritoneal mesotheliomas (MPMs) are rare tumors with overlapping clinical and histopathological features, especially with epithelial ovarian carcinomas (EOCs). There is no substantial documentation on these rare tumors from our country. Objective: To study the…
Read MoreProtocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)
BMJ Open 2022 November 10 [Link] Ruairi J H Conway, Jenny Symonds, Deborah Walton, Janet Probets, Charles Comins, Louise Stadon, John E Harvey, Kevin G Blyth, Nick A Maskell, Anna C Bibby Abstract Introduction: Mesothelioma is a heterogeneous disease that can be challenging to monitor and prognosticate. ASSESS-meso is a multicentre, prospective, longitudinal observational cohort…
Read MoreRhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma
Scientific Reports 2022 November 2 [Link] Takuya Hiratsuka, Takushi Yamamoto, Akihiko Yoshizawa, Shinya Toyokuni, Tatsuaki Tsuruyama Abstract Diagnostic markers of malignant mesothelioma (MM) have been extensively investigated. Immunohistochemistry (IHC) markers, such as calretinin, have been used for pathologic diagnosis. However, more diagnostic markers are required to improve the specificity and sensitivity of pathologic diagnosis. This…
Read MoreThe extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling
Frontiers in Oncology 2022 October 11 [Link] Arivazhagan Roshini, Chandra Goparaju, Somanath Kundu, Mohan S Nandhu, Sharon L Longo, John A Longo, Joan Chou, Frank A Middleton, Harvey I Pass, Mariano S Viapiano Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis and limited therapeutic options. The extracellular matrix protein fibulin-3/EFEMP1 accumulates…
Read MoreBlood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort
International Journal of Cancer 2022 October 28 [Link] Alessandra Allione, Clara Viberti, Ilaria Cotellessa, Chiara Catalano, Elisabetta Casalone, Giovanni Cugliari, Alessia Russo, Simonetta Guarrera, Dario Mirabelli, Carlotta Sacerdote, Marco Gentile, Fabian Eichelmann, Matthias B Schulze, Sophia Harlid, Anne Kirstine Eriksen, Anne Tjønneland, Martin Andersson, Martijn E T Dollé, Heleen Van Puyvelde, Elisabete Weiderpass, Miguel Rodriguez-Barranco,…
Read MoreUtility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology
Cancer Medicine 2022 October 19 [Link] Anders Hjerpe, Enes Demir, Sulaf Abd-Own, Katalin Dobra Abstract Background: Pleural mesothelioma (PM) is typically diagnosed late during the disease. Earlier detection can increase the chance of effective therapy. Recurrent pleural effusions are the earliest symptoms displaying an array of cytomorphological changes from reactive atypia to malignancy. Diagnosis is…
Read MoreAssessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis
PLoS One 2022 October 14 [Link] Carmina Jiménez-Ramírez, Daniel Gilbert Weber, Guadalupe Aguilar-Madrid, Alexander Brik, Cuauhtémoc Arturo Juárez-Pérez, Swaantje Casjens, Irina Raiko, Thomas Brüning, Georg Johnen, Alejandro Cabello-López Abstract Malignant pleural mesothelioma (MPM) is a cancer associated with asbestos exposure and its diagnosis is challenging due to the moderate sensitivities of the available methods. In…
Read MoreEmerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy
International Journal of Radiation Oncology, Biology, Physics 2022 October 3 [Link] Michela Cangemi, Marcella Montico, Marco Trovo, Emilio Minatel, Emanuela Di Gregorio, Giuseppe Corona, Fabiana Giordari, Elisa Comaro, Francesca Colizzi, Lorena Baboçi, Agostino Steffan, Alberto Revelant, Elena Muraro Abstract Purpose: The present study aimed at evaluating the baseline immune profile and the immunomodulating effects of…
Read More